Summary:
Ready to SHINE a new light on Alzheimer’s disease?
Consider joining this research study!
Adults Living with Mild-to-Moderate Alzheimer’s disease Needed for a Research Study
The SHINE study is a phase 2 study evaluating the safety and efficacy of the study drug CT1812 in adults ages 50 to 85 who have been diagnosed with mild to moderate Alzheimer’s disease. An estimated 6.5 million Americans aged 65 and older are living with Alzheimer’s in 2022. Alzheimer’s disease is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.
The total duration of the participation in the study is approximately 8 months including screening.
Participants enrolled in the study will be randomly assigned to 1 of 3 groups:
Group 1: Will take 100 mg of CT1812 (2 capsules) once daily
Group 2: Will take 300 mg of CT1812 (2 capsules) once daily
Group 3: Will take the placebo (2 capsules) once daily.
If you take part in the clinical study, your caregiver must accompany you to all of your visits, help you with taking the study medication in between visits, and help you report how you’re feeling at each visit.
You or a Loved One May Qualify If You or They:
- Are between the ages of 50 to 85
- Have been diagnosed with mild to moderate Alzheimer’s disease
- Have a caregiver or study partner who is willing and able to attend all study visits and participate in some study assessments
- Have not had a history of cancer within the last 3 years
There is no cost to participate in the SHINE study. Eligible participants may receive reimbursement for time and travel-related expenses (including long-distance travel). Study-related medications and examinations are offered at no cost to eligible participants.